How Anti-Doping Labs Detect Banned Peptide Drugs: A Faster, Simpler Testing Method | Research

The takeaway

A new high-throughput testing method using liquid chromatography-mass spectrometry can detect banned peptide drugs in sports at concentrations as low as 50-200 pg/mL with minimal sample preparation.

50-200 pg/mL detection limits
The method can detect banned peptide drugs at concentrations of 50-200 picograms per milliliter — detecting billionths of a gram in a single milliliter of sample.

What the researchers found

The new assay achieved detection limits of 50-200 pg/mL for banned peptidic drugs under 2 kilodaltons, covering:

• Gonadotropin releasing hormone (GnRH) and its analogs

• Growth hormone secretagogues (GHS)

• Growth hormone releasing peptides (GHRPs)

• Desmopressin (a vasopressin analog)

The 'dilute-and-inject' strategy eliminated complex sample preparation while maintaining high sensitivity and specificity. The method combined two-dimensional liquid chromatography, DMSO-assisted electrospray ionization, and high-resolution mass spectrometric detection. A tailored reporter template facilitated rapid data review, enabling high-throughput screening.

Why it matters

Peptide doping is one of the hardest forms of cheating to detect in sports because peptide drugs are present in very small amounts and break down quickly in the body. This method makes routine peptide screening faster and more practical, closing a gap that some athletes have exploited. As more performance-enhancing peptides enter the black market, anti-doping labs need efficient methods to keep up — and this 'dilute-and-inject' approach dramatically simplifies the process.

How the study worked

The researchers developed and validated a liquid chromatography-mass spectrometry (LC-MS) assay for detecting small peptidic drugs in biological samples. The approach used a 'dilute-and-inject' sample preparation strategy, two-dimensional liquid chromatography for separation, DMSO-enhanced electrospray ionization for improved sensitivity, and high-resolution mass spectrometry for detection. A custom reporter template was created to streamline data review for routine screening.

What this study cannot tell us

The abstract describes the analytical method development but does not report validation data from real athlete samples or false positive/negative rates. Detection limits of 50-200 pg/mL, while impressive, may still miss some peptides administered at very low doses or with short detection windows. The method covers specific classes of peptides under 2 kDa and may not detect newer designer peptides outside these categories. Real-world matrix effects from diverse athlete urine samples could affect performance.

How to read the evidence

This is a methods development paper presenting a novel analytical assay. It demonstrates technical capability and performance characteristics but is not a clinical study. Evidence quality is assessed based on methodological rigor and validation approach.

When this study was published

Published in 2018, this method represents the state of anti-doping testing technology from that period. LC-MS methods continue to improve, and newer approaches may have surpassed these detection limits. However, the dilute-and-inject strategy remains influential.

The bigger picture

The peptide doping landscape is constantly evolving as new growth hormone secretagogues, GnRH analogs, and other peptide drugs emerge from underground labs and research chemical suppliers. Anti-doping testing must evolve in parallel. This work represents a significant step toward making peptide drug testing as routine and efficient as testing for traditional small-molecule drugs like steroids — critical for maintaining fair competition in elite sports.

Questions still open

How does this method perform on real athlete samples compared to spiked laboratory standards?
Can the assay be expanded to cover newer peptide drugs and designer analogs entering the black market?
What is the detection window — how long after administration can these peptides still be found?

Common questions

Why are peptide doping drugs harder to detect than steroids?

Peptide drugs are present in much smaller amounts than steroids, break down quickly in the body (often within hours), and many are similar to natural hormones your body already produces. Traditional steroid tests look for synthetic molecules that don't naturally exist — but with peptides, the lab has to distinguish tiny amounts of injected peptide from the body's own production, requiring extremely sensitive mass spectrometry techniques.

What peptide drugs do athletes use for performance enhancement?

The main categories are growth hormone releasing peptides (GHRPs like GHRP-6 and hexarelin) that stimulate growth hormone release, growth hormone secretagogues (like ipamorelin and MK-677), GnRH analogs that manipulate testosterone production, and desmopressin which can alter blood concentration. All are banned by WADA but are available on the black market.

Read the original research

Recent improvements in sports drug testing concerning the initial testing for peptidic drugs (< 2 kDa) - sample preparation, mass spectrometric detection, and data review.

Drug testing and analysis, 10(11-12), 1755-1760

View on PubMed ↗Publisher’s paper ↗

Citation

Görgens, Christian; Guddat, Sven; Thomas, Andreas; Thevis, Mario. (2018). Recent improvements in sports drug testing concerning the initial testing for peptidic drugs (< 2 kDa) - sample preparation, mass spectrometric detection, and data review.. Drug testing and analysis, 10(11-12), 1755-1760. https://doi.org/10.1002/dta.2503